HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Vidarabine

HCID 21704
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
24356-66-9
Standard SMILES
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
InChIKey
OIRDTQYFTABQOQ-UHTZMRCNSA-N
Molecular formula
C10H13N5O4
Average molar mass
267.24 g/mol
Monoisotopic mass
267.09675391

Overview

Vidarabine is a white to off-white crystalline powder. (NTP, 1992)

Names & identifiers

Preferred name
Vidarabine
IUPAC
(2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
English name
VIDARABINE (200 MG)G-2939UG/MG(AI)
Molecular formula
C10H15N5O5
Molecular weight
285.2566

Names & synonyms

Vidarabine5536-17-4Adenine arabinosideAra-AArabinosyladenineSpongoadenosineVira-AAraadenosineArasena-AVidarabin9-beta-D-ArabinofuranosyladenineVidarabine anhydrous
Show more names
Vidarabine H2OVira-A monohydrateVidarabine (200 mg)Vidarabine 1-hydrateVidarabine monohydrate uspSpongoadenosine monohydrateVIDARABINE (200 MG)G-2939UG/MG(AI)9-SS-D-ARABINOFURANOSYLADENINE HYDRATE9-(b-D-Arabinofuranosyl)adeninemonohydrate9-beta-d-arabinofuranosyl-adeninmonohydrate
VidarabinaVidarabinumbeta-D-ArabinosyladenineNSC-4042419-beta-D-arabinofuranosyl-9H-purin-6-amine9-Arabinosyladenine9-beta-ArabinoadenosineVira A

Database identifiers

CAS
24356-66-9、5536-17-4
PubChem CID
21704
DTXSID
DTXSID80873976

Properties

Computed structural properties

XLogP
-1.1
Topological polar surface area
140 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
8
Rotatable bonds
2
Heavy atoms
19
Formal charge
0
Complexity
335

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceutical

LogP · 2 items

log Kow = -1.11

-2.115

Color/Form · 2 items

Crystals from water

Needles from water

Solubility · 4 items

less than 1 mg/mL at 70 °F (NTP, 1992)

The monohydrate occurs as a white, crystalline powder and has a solubility of approximately 0.45 mg/mL in water at 25 °C. /Vidarabine monohydrate/

1.40e+01 g/L

>40.1 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

DecompositionWhen heated to decomposition it emits very toxic fumes of /nitrogen oxides/.
Melting Point · 3 items

500 to 518 °F (NTP, 1992)

257.0-257.5 °C (0.4 H2O)

257.00 °C. @ 760.00 mm Hg

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H361 (97.6%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory.

Hazard information

Fire HazardsFlash point data for this chemical are not available; however it is probably combustible. (NTP, 1992)
Health Hazards · 1 item

SYMPTOMS: Symptoms of exposure to this compound include nausea, vomiting, diarrhea, rash, weakness, thrombophlebitis, hallucinations, psychoses, ataxia, tremor, and dizziness. It can cause gastrointestinal disturbances, confusion, anemia, leukopenia, thrombocytopenia, elevated liver enzymes and bilirubin, corneal changes, and sensitivity changes. In addition, it causes mild itching and irritation of the eyes, and moderate redness of the conjunctiva with temporary punctate keratitis. Anorexia, weight loss, and abnormal EKG have been reported. It causes headache, encephalopathy, decrease in hemoglobin, white blood count, platelet count, and malaise, pruritus, and hematemesis.

FDA Requirements · 2 items

Proposed regulation to exempt marketing applications for certain antibiotic drug products, including vidarabine, from regulatory provisions governing marketing exclusivity and patents.[Federal Register: January 24, 2000 (Volume 65, Number 15)

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies discontinued drug products. Vidarabine is included on this list.

Reactive GroupAlcohols and Polyols
Reactivity Profile

Chemistry & industry

Pharmacology

ATC Code · 4 items

S - Sensory organs

J - Antiinfectives for systemic use

QS - Sensory organs

QJ - Antiinfectives for systemic use

Protein Binding24-38%
Pharmacodynamics · 1 item

Vidarabine is a synthetic purine nucleoside analogue with <i>in vitro</i> and <i>in vivo</i> inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. <i>In vitro</i>, Vidarabine triphosphate stops the DNA replication of herpes virus by being incorporated into the DNA strand and preventing the formation of phosphodiester bridges between bases. This ultimately leads to destabilization of the viral DNA strands.

Mechanism of Action · 3 items

Vidarabine stops replication of herpes viral DNA in 2 ways: 1) competitive inhibition of viral DNA polymerase, and consequently 2) incorporation into and termination of the growing viral DNA chain. Vidarabine is sequentially phosphorylated by kinases to the triphosphate ara-ATP, which is the active form of vidarabine that acts as both an inhibitor and a substrate of viral DNA polymerase. By acting as a substrate for viral DNA polymerase, ara-ATP competitively inhibits dATP leading to the formation of ‘faulty’ DNA. Ara-ATP can also be incorporated into the DNA strand to replace many of the adenosine bases, resulting in the disruption of DNA synthesis.

The antiviral mechanism of action has not been established. Vidarabine appears to interfere with the early steps of viral DNA synthesis.

The antiviral mechanism of vidarabine is incompletely understood, but vidarabine is an inhibitor of viral DNA synthesis. Cellular enzymes phosphorylate vidarabine to the triphosphate, which inhibits viral DNA polymerase activity in a manner that is competitive with deoxyadenosine triphosphate. Vidarabine triphosphate is incorporated into both cellular and viral DNA, where it may act as a chain terminator. Vidarabine triphosphate also inhibits ribonucleoside reductase, RNA polyadenylation, and S-adenosylhomocysteine hydrolase (SAHH), an enzyme involved in transmethylation reactions.

Related reactions

10 records
New reaction record
HRID 408080 reaction equation
HRID 408080As product
HRID 439284 reaction equation
HRID 439284As productAs reactant
HRID 504988 reaction equation
HRID 504988As product
HRID 504989 reaction equation
HRID 504989As product
HRID 618423 reaction equation
HRID 618423As productAs reactant
HRID 1072405 reaction equation
HRID 1072405As product
HRID 1072406 reaction equation
HRID 1072406As product
HRID 1834312 reaction equation
HRID 1834312As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL1090
ChEBI
CHEBI:45327
UNII
3XQD2MEW34
EC Number
226-893-9
Nikkaji
J3.415K
Optical Rotation
Specific optical rotation: -5 deg at 27 °C/D (concentration by volume= 0.25 g in 100 ml water).
Physical Description · 2 items

Vidarabine is a white to off-white crystalline powder. (NTP, 1992)

Solid

Stability/Shelf LifeVidarabine ophthalmic ointment should be stored at a temperature less than 40 °C, preferably between 15-30 °C; freezing should be avoided.
Collision Cross Section · 2 items

156.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

154.43 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
253 °C · 253 °C
Boiling point
427.69 °C · 427.69°C (rough estimate)
Density
1.3439 · 1.3439 (rough estimate)
refractive index
-3 ° · -3.0 ° (C=1, DMF)
storage temp.
Keep in dark place,Inert atmosphere,Room temperature
solubility
soluble in Dimethylformamide
form
powder to crystal
color
White to Almost white
Water Solubility
513.5 mg/L · 513.5mg/L(temperature not stated)
Merck
14 · 14,9976
InChI
1S/C10H13N5O4.H2O/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10;/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13);1H2/t4-,6-,7+,10-;/m1./s1
InChIKey
ZTHWFVSEMLMLKT-CAMOTBBTSA-N
SMILES
NC1=NC=NC2=C1N=CN2[C@@H]3O[C@@H]([C@H]([C@@H]3O)O)CO.O
FDA UNII
2 DM6879K · FA2DM6879K
UNSPSC Code
12352200 · 12352200
NACRES
21 · NA.21
Symbol(GHS)
8 · GHS08
Signal word
Warning
Hazard statements
361 · H361
Precautionary statements
201 · P201-P202-P281-P308+P313-P405-P501
Risk Statements
62 · 62
Safety Statements
45 · 45-53-36/37
WGK Germany
3 · WGK 3
RTECS
6200000 · AU6200000
HS Code
29349990 · 29349990
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 · Repr. 2
· 1 item

VIDARABINE is an organic compound containing both amine and alcohol substituents. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

Air and Water ReactionsInsoluble in water.
Hazard Classes and CategoriesRepr. 2 (97.6%)
Skin, Eye, and Respiratory IrritationsBurning, itching, and mild irritation of the affected eye are the most common adverse effects of topical vidarabine therapy.

Safety & protection

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Preventive Measures · 1 item

SRP: The scientific literature for the use of contact lenses in industry is conflicting. The benefit or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.

Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxicology

Interactions · 2 items

Although an interaction has not been clearly established, concurrent administration of vidarabine and allopurinol has been associated with tremors, anemia, nausea, pain, and pruritus in some patients. Animal and in vitro studies suggest that allopurinol may interfere with the metabolism of vidarabine.

Acyclovir and vidarabine both exhibit anti-herpetic activity. Because different mechanisms of action of vidarabine and acyclovir have been reported, /the authors/ analyzed their combined anti-herpetic activity on plaque formation of herpes simplex virus (HSV)-1, HSV-2, and varicella-zoster virus (VZV) by isobolograms. The results indicate that acyclovir and vidarabine have a synergistic effect on wild type HSV-1, HSV-2, and VZV. ...

Health EffectsChronically high levels of adeonsine are associated with Adenosine Deaminase Deficiency.
Toxicity Summary · 1 item

Adenosine slows conduction time through the AV node and can interrupt the reentry pathways through the AV node, resulting in the restoration of normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. This effect may be mediated through the drug's activation of cell-surface A<sub>1</sub> and A<sub>2</sub> adenosine receptors. Adenosine also inhibits the slow inward calcium current and activation of adenylate cyclase in smooth muscle cells, thereby causing relaxation of vascular smooth muscle. By increasing blood flow in normal coronary arteries with little or no increase in stenotic arteries (with little to no increase in stenotic arteries), adenosine produces a relative difference in thallous (thallium) chloride TI 201 uptake in myocardium supplied by normal verus stenotic coronary arteries.

Human Toxicity Excerpts · 4 items

/SIGNS AND SYMPTOMS/ Ocular toxicity /including/ punctate keratopathy and hypersensitivity /may occur when using/ topical vidarabine (VIVA-A; 3% ointment) /to treat/ herpes simplex keratitis and conjunctivitis. /From table/

/SIGNS AND SYMPTOMS/ Iv vidarabine causes dose-related GI toxicity, acute neurotoxicities, painful peripheral neuropathy, weakness, hypokalemia, rash, elevated transaminases, anemia, and leukopenia or thrombocytopenia.

/SIGNS AND SYMPTOMS/ Like other ophthalmic ointments, vidarabine may produce a temporary visual haze. Burning, itching, and mild irritation of the affected eye are the most common adverse effects of topical vidarabine therapy; however, lacrimation, foreign body sensation, conjunctival injection, superficial punctate keratitis, pain, photophobia, punctal occlusion, and sensitivity may also occur. Uveitis, stromal edema, secondary glaucoma, trophic defects, corneal vascularization, and hyphema have also been reported, but appear to be disease related.

/GENOTOXICITY/ In vitro, the drug has been shown to cause chromosome breaks and gaps when added to human leukocytes...

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

vidarabine

DILI Negative

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Acute Exposure/ ... very little toxicity to the eye /of rabbits/.[Grant, W.M. Toxicology of the Eye. 3rd ed. Springfield, IL: Charles C. Thomas Publisher, 1986., p. 973]

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Hepatic megalocytosis has also been associated with vidarabine use in rodents, but it is not known if this represents a preneoplastic condition.[McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 93. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1993 (Plus Supplements, 1993)., p. 405]

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ There is some evidence that vidarabine can cause mutagenic or tumorigenic effects in animals (eg, liver tumors and kidney neoplasia in mice; intestinal, testicular, and thyroid neoplasia in rats). ...[McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 93. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1993 (Plus Supplements, 1993)., p. 405]

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Vidarabine is teratogenic in rats and rabbits. Although there are no adequate and controlled studies to date in humans, vidarabine has been shown to induce fetal abnormalities in rabbits when given during fetal organogenesis at an im dosage of 5 mg/kg; teratogenic effects were not observed at dosages of 3 mg/kg or less. Vidarabine caused maternal toxicity at im dosages of 100 mg/kg or greater in rats, and frank fetal abnormalities occurred at dosages of 150-250 mg/kg.[McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 93. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1993 (Plus Supplements, 1993)., p. 405]

For more Non-Human Toxicity Excerpts (Complete) data for VIDARABINE (9 total), please visit the HSDB record page.

Populations at Special Risk · 3 items

Administration of the large volume of iv solution required to solubilize vidarabine may cause fluid overload in patients with CNS infections or impaired renal function. Vidarabine should be used with caution in patients with impaired liver or kidney function and in patients susceptible to fluid overload or cerebral edema. Serum AST (SGOT) concentration, leukocyte and platelet counts, hemoglobin, and hematocrit should be monitored in patients receiving the drug. Vidarabine is contraindicated in patients who are hypersensitive to the drug or any ingredient in the formulation.

The safety and effectiveness in pediatric patients below the age of 2 years have not been established.

A safe dosage of the drug for use in pregnant women has not been established. Vidarabine should be used during pregnancy only if the potential benefits outweigh the possible risks to the fetus. ... It is not known if vidarabine is distributed into milk. Because of the potential for serious adverse reactions from vidarabine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

Probable Routes of Human ExposureNIOSH (NOES Survey 1981-1983) has statistically estimated that 1,307 workers (664 of these are female) are potentially exposed to vidarabine in the US(1).
Non-Human Toxicity Values · 5 items

LD50 Mouse iv 442 mg/kg

LD50 Mouse sc 5086 mg/kg

LD50 Mouse ip 3057 mg/kg

LD50 Mouse oral 7800 ug/kg

For more Non-Human Toxicity Values (Complete) data for VIDARABINE (7 total), please visit the HSDB record page.

Regulatory information

FDA Requirements · 2 items

Proposed regulation to exempt marketing applications for certain antibiotic drug products, including vidarabine, from regulatory provisions governing marketing exclusivity and patents.[Federal Register: January 24, 2000 (Volume 65, Number 15)

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies discontinued drug products. Vidarabine is included on this list.

Safety data

wgk
WGK 3
rtecs
AU6200000
hs_code
29349990
risk_code
62
Signal word
Warning
Symbol(GHS)
GHS08
safety_code
45-53-36/37
Storage Class
11 - Combustible Solids
Hazard statements
H361
Hazard Classifications
Repr. 2
Precautionary statements
P201-P202-P281-P308+P313-P405-P501
Biological Half-LifeThe plasma half-life of vidarabine in adults with normal renal function is 1.5 hr, and the plasma half-life of ara-hypoxanthine is 3.3 hr.
Metabolism/Metabolites · 4 items

In laboratory animals, vidarabine is rapidly deaminated in the gastrointestinal tract to Ara-Hx.

In laboratory animals, Vira-A is rapidly deaminated in the gastrointestinal tract to arabinosylhypoxanthine (Ara-Hx).

Vidarabine is rapidly deaminated, possibly within the cornea, by adenosine deaminase to ara-hypoxanthine. Ara-hypoxanthine also possesses antiviral activity but substantially less than that of vidarabine.

Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Half Life: Less than 10 secs

MeSH Pharmacological Classification · 2 items

Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033)

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Absorption, Distribution and Excretion · 5 items

Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions.

Vira-A is rapidly deaminated to arabinosylhypoxanthine (Ara-Hx), the principal metabolite. ...Because of the low solubility of Vira-A, trace amounts of both Vira-A and Ara-Hx can be detected in the aqueous humor only if there is an epithelial defect in the cornea. If the cornea is normal, only trace amounts of Ara-Hx can be recovered from the aqueous humor. Systemic absorption of Vira-A should not be expected to occur following ocular administration and swallowing lacrimal secretions.

Vidarabine is poorly absorbed following oral, im, or SC administration. Following iv administration of vidarabine, 75-87% of the dose is rapidly deaminated by adenosine deaminase to ara-hypoxanthine. Ara-hypoxanthine also possesses antiviral activity but substantially less than that of vidarabine. Following slow iv administration of vidarabine 10 mg/kg in adults, peak plasma concentrations of the drug range from 0.2-0.4 ug/mL and peak plasma concentrations of ara-hypoxanthine range from 3-6 ug/mL. Plasma concentrations of vidarabine and ara-hypoxanthine are higher and more prolonged in patients with renal impairment.

Vidarabine and ara-hypoxanthine are widely distributed into body tissues and fluids and readily cross the blood-brain barrier. In patients with normal meninges, ara-hypoxanthine concentrations in the CSF are about 33-35% of concurrent plasma concentrations. Vidarabine crosses the placenta in animals. It is not known if vidarabine is distributed into milk. ... Vidarabine is 20-30% bound and ara-hypoxanthine is 0-3% bound to plasma proteins.

Vidarabine and ara-hypoxanthine are excreted mainly by the kidneys. Within 24 hours following iv administration of vidarabine 15 mg/kg in patients with normal renal function, 1-3% of the dose is excreted in urine as vidarabine and 41-53% of the dose is excreted as ara-hypoxanthine. There is no evidence of fecal excretion of the drug or metabolite.

Cellular LocationsCytoplasm

Uses & manufacturing

Uses · 6 items

MEDICATION

THERAP CAT: ANTIVIRAL

A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus

VIRA-A Vidarabine, 3% ointment, ophthalmic: Discontinued

VIRA-A (vidarabine) eq 187.4 mg base/ml, injectable; injection: Discontinued

Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.

Methods of ManufacturingOriginally prepared by chemical synthesis at Stanford Research Institute, and later isolated from a fermentation beer of Streptomyces antibioticus.
Formulations/Preparations · 3 items

Ophthalmic Ointment 3% (equivalent to vidarabine, Vira-A, Parke-Davis anhydrous 2.8%)

Parenteral: Concentrate, for injection, for iv infusion, 200 mg/ml (equivalent to 187.4 mg of anhydrous vidarabine per ml). Vira-A (with benzethonium chloride and phosphate buffers), Parke-Davis

/Vidarabine/ not currently approved for use in the United States

General Manufacturing Information9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-: INACTIVE

Applications

UsesAntiviral.

Additional notes · 1 item

DefinitionA biologically active pharmaceu- tical product having both antitumor and antiviral properties. It was originally prepared (1959) by chemical synthesis at Stanford Research Institute, and later isolated from a fermentation beer of Strep- tomyces antibioticus.